MedTrace Logo

A Study to Evaluate the Safety and Performance of Dr Korman Laboratories' Hyaluronic Acid Filler 20 mg/mL With Lidocaine for Lip Augmentation

NCT07204691 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2026-05-15

No results posted yet for this study

Summary

This study will assess the safety and effectiveness of a dermal filler called DKL crosslinked hyaluronic acid 20 mg/mL with lidocaine 0.3% when injected into the lips of healthy men and women who want to have fuller lips. The change in the appearance of the lips will be checked.

Conditions

  • Lip Augmentation

Interventions

DEVICE

DKL crosslinked sodium hyaluronate 20 mg/mL + Lidocaine 0.3% dermal filler

DKL crosslinked sodium hyaluronate 20 mg/mL + lidocaine 0.3% dermal filler is an injectable sterile, non-pyrogenic gel composed of crosslinked sodium hyaluronate of a non-animal origin and lidocaine in a phosphate-buffered saline solution.

Sponsors & Collaborators

  • CTC Clinical Trial Consultants AB

    collaborator INDUSTRY

  • Dr. Korman Laboratories Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-24
Primary Completion
2026-02-12
Completion
2026-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07204691 on ClinicalTrials.gov